Followers | 3350 |
Posts | 84729 |
Boards Moderated | 6 |
Alias Born | 10/05/2005 |
Wednesday, November 01, 2023 5:58:00 AM
October 31 2023 - 07:00AM
GlobeNewswire Inc.
Alert
Share On Facebook
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International mRNA Health Conference taking place in Berlin, Germany, October 31 – November 2, 2023.
“These new preclinical data show that, through deep understanding of disease biology and genomic architecture, our OMEGA platform is able to design a programmable mRNA candidate capable of multiplexing to pre-transcriptionally control the expression of multiple genes in preclinical models,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “By targeting a genomic locus containing a cluster of cytokine genes, we can precisely modulate immune activity to elicit a meaningful anti-inflammatory response. The potential applications of this strategy extend beyond any single disease and highlight the broad potential of precision epigenomic control.”
Details for the poster presentation:
Title: Design and Characterization of a Programmable Epigenomic Controller Demonstrating
Multiplexed Targeting of the CXCL1-8 Gene Cluster for Treatment of Inflammatory Disorders
Poster #: 79
Session information: Flash Poster Talks / New Company Introductions Session
Date and Time: Tuesday, October 31, 2023, from 4:00 pm to 5:00 pm CET
Key Findings:
Treatment of human lung fibroblasts with CXCL1-8-targeting ECs correlated with corresponding decrease in gene expression of multiple CXCL chemokines
EC-induced changes in the epigenetic profiles of the CXCL1-8 genes were associated with decreased binding of NF-kB
Human lung fibroblasts treated with a single CXCL-EC engineered to modulate the epigenetic profiles of the CXCL1-8 gene cluster showed downregulation of both mRNA and protein levels of CXCL1, 2 and 8
Cells treated with a CXCL-EC showed decreased ability to support neutrophil migration in vitro
In a mouse model of lung inflammation, single administration of a mouse surrogate CXCL-EC resulted in decreased recruitment of neutrophils and B and T cells into bronchoalveolar fluid
The poster will be available on the Omega website at https://omegatherapeutics.com/science/publications at the same time as the presentation.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on X (formerly Twitter) and LinkedIn.
Recent OMGA News
- Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 11:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 11:04:21 AM
- Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/06/2024 11:00:02 AM
- Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/23/2024 11:00:02 AM
- Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control • GlobeNewswire Inc. • 04/09/2024 11:00:31 AM
- Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update • GlobeNewswire Inc. • 03/28/2024 01:15:05 PM
- Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:14:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:59:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:00:18 PM
- Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 09:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 12/04/2023 09:00:22 PM
- Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders • PR Newswire (US) • 11/28/2023 12:01:00 AM
- Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics • PR Newswire (US) • 11/21/2023 11:00:00 AM
- Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 09:00:00 PM
- Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis • GlobeNewswire Inc. • 11/13/2023 12:00:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:03:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:03:00 PM
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 11/09/2023 12:00:17 PM
- Omega Therapeutics to Participate in The Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/07/2023 09:00:20 PM
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller • GlobeNewswire Inc. • 10/31/2023 11:00:16 AM
- Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC • GlobeNewswire Inc. • 10/16/2023 11:00:46 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM